Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Atopic eczema and eczema variants
- Atopic eczema
- Epidemiology of AE
- Atopic eczema impairs ability to work
- Atopic eczema impact on mental health
- Atopic eczema: disease course
- Diagnostic criteria & clinical features
- Atopic eczema: Hanifin and Rajika criteria
- Atopic/non-atopic, extrinsic/intrinsic eczema
- Atopic eczema: criteria
- Atopic eczema in adults
- Atopic eczema in infants
- Severe atopic eczema
- Appearance of atopic eczema
- Complications of atopic eczema
- Staphylococcal super-infection
- Eczema herpeticum
- Trigger factors
- AE microbial diversity
- Food allergy
- Cochrane review
- Egg exclusion diet vs. general advice
- DBPCFC in children with AE
- Cochrane review: possible conclusions
- The message
- Allergic co-morbidities
- Allergic march
- Challenges to allergic march concept
- Pathophysiology
- Epidermal barrier function in AE
- Genetics
- GWAS – atopic eczema
- Fillaggrin common loss of function variants
- Filaggrin
- Environment
- Postnatal antibiotic exposure and eczema risk
- The immune system is important for AE
- IgE
- T cells in AE pathogenesis
- T cells are central to pathogenesis
- Why Th2 responses:
- Changing immunophenotype
- Immune responses overview
- Immune responses: summary
- Current treatment
- Aetiology of atopic eczema
- What causes atopic eczema?
- Emollients
- Clothing/bandages
- Topical steroids
- Topical steroid side effects
- Calcineurin inhibitors
- Targeting microbes in AE
- Treatment flowchart
- Future treatment
- Filaggrin copy number – affects expression levels
- Restoration of filaggrin status
- Coal tar up-regulates filaggrin expression
- Preventing complications from barrier function loss
- Anti-Th2?
- CRTH2 inhibitors
- Many roads lead to Rome
- Atopic eczema remains a complex disease
- We need to use biomarkers in trials
- Conclusions
Topics Covered
- Atopic eczema and eczema variants (epidemiology and impact of AE)
- Diagnostic criteria & clinical features
- Complications of atopic eczema
- Trigger factors
- Allergic comorbidities
- Pathophysiology
- Current treatment
- Future treatment
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Ardern-Jones, M. (2016, September 29). Atopic eczema/atopic dermatitis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 14, 2024, from https://doi.org/10.69645/ZMJE6017.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Michael Ardern-Jones has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Allergy - From Basics to Clinic
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. I'm Michael Ardern-Jones.
Associate Professor of Dermatology and Clinical Consultant
Dermatologist at the University of Southampton.
Today, I'm going talk to you about "Atopic Eczema".
This title slide reminds me to emphasize that the term
atopic eczema is synonymous with the term atopic dermatitis.
The two are completely interchangeable.
If I use atopic eczema throughout subsequent slides,
then you could also replace that with atopic dermatitis.
0:28
Atopic eczema is one of a variety of different eczemas
and I've listed here some different variants of eczema,
which I'm not going to focus on in this presentation.
Instead, I'm going to talk about atopic eczema,
which is characterized by an itchy,
chronically relapsing inflammatory skin condition.
It is much more prevalent in childhood than in adulthood.
0:50
I'm going talk to you about epidemiology,
diagnostic criteria and clinical features,
co-morbidities, genetics, immunology, allergy, and current management.
Then I'm going to move on to future management of the disease.
1:05
Epidemiology of atopic dermatitis has been studied for a long time,
and one of the most important studies has been
the International Study on Asthma and Allergies in Childhood,
which looked at the prevalence of allergies including eczema in 106 countries.
This study was able to undertake a global prevalence measurement of atopic eczema.
You can see here that although there was a wide range of
prevalence in atopic eczema in different countries,
that actually this is a common disease in children.
The UK, as you can see,
lies at the upper end of the prevalence range,
and this is reflected in the health demands in our country.
A recent systematic review of prevalence studies has
shown that lifetime prevalence of atopic eczema is
approximately 20 percent in Western countries.
This is in fact increasing year-on-year.
A recent study looked at the prevalence in different age groups of children,
and you can see here how the majority of atopic eczema arises in the first year of life.
Adult atopic eczema is far less common and affects 1-3 percent of adults.
Atopic eczema is important and it's been shown